Frank Morich
Independent DirectorDr. Frank Morich, M.D., Ph.D., is an Independent Director at Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) since February 5, 2023. He serves as a Director at Viewpoint Molecular Targeting, Inc. He served as the Chairman of the Board for Cue Biopharma, Inc. since April 2020 and served as its Independent Director since July 2018 until May 29, 2026. Dr. Morich served on the board of directors of Viewpoint from February 2021 until February 3, 2023. He is the Executive Chairman of Aphaia Pharma, located in Zug, Switzerland, a clinical-stage biopharmaceutical company focused on treating and preventing metabolic disorders such as obesity and diabetes, a position he has held since June 2022. Dr. Morich has been a consultant in the life sciences and health care industries since 2015. He served as Chief Executive Officer of Nycomed A/S and Nycomed International Management GmbH since September 30, 2011. He was the Chief Commercial Officer at Takeda Pharmaceutical Company Limited from November 2011 to April 1, 2014 and served as Executive Vice President of International Operations - Americas/Europe at Takeda Pharmaceutical Co. Ltd. (Takeda Pharmaceuticals International, Inc.) from October 1, 2010, to 2011, also serving as its Advisor. Dr. Morich was the Chief Executive Officer and Executive Director of Fujirebio Europe N.V. from 2005 to October 2007 and served as the Chief Executive Officer of NOXXON Pharma AG from January 2008 to August 15, 2010. He was the Chief Executive Officer at Innogenetics NV from January 2005 to October 15, 2007 and served as Chief Executive Officer of Takeda Pharmaceuticals International GmbH since September 30, 2011. In 2004, Dr. Morich served as Chief Executive Officer and Chairman of the Executive Board of AM Pharma B.V. He was a Member of the Management Board of Bayer AG until June 30, 2002, where he was Head of Global Product Development and Head of Research and Development and in 1998, he became the General Manager of Bayer AG’s Consumer Care Division. He also served as Chief Executive Officer of Innate Pharma SA. Dr. Morich joined Bayer in 1982 and held various roles within the Pharmaceutical Division, including Head of Research and Development and Head of Global Product Development. He served as Deputy Chairman of the Supervisory Board at Morphosys AG until April 11, 2020 and was on the board of directors for Morphosys from 2015 to 2021 and for Innate Pharma from 2004 to 2010. He served as Vice-Chairman of the Supervisory Board at Innate Pharma SA until May 2010 and was a Member of the Supervisory Board from March 19, 2004, to May 2010. Dr. Morich is a Member of the Senate of Fraunhofer-Gesellschaft for Applied Research and has been a Director of Takeda Pharmaceuticals International, Inc. since June 24, 2011. He was a Member of the Supervisory Board at Morphosys AG from May 8, 2015, until April 11, 2020 and served on the Supervisory Board at AM-Pharma B.V. He was a Director of Takeda Pharmaceutical Co. Ltd since 2011 and served as Non-Executive Director of Neuro3d SA since September 2005. He served as Executive Director of Innogenetics NV from January 2005 to October 15, 2007 and held the position of Chief Executive Officer, also serving as its Independent Director. Dr. Morich has served as a Director of Innate Pharma SA, Bayer (Germany) and Bayer Corp. (USA). He obtained a medical degree from the University of Marburg (Germany) and conducted post-doctoral research in immunology and cellular biology in 1980. He holds both an M.D. and a Ph.D. from the University of Marburg, specializing in immunology with a focus on monoclonal antibodies and he also served as a military physician.
Positions
- Company NamePerspective Therapeutics, Inc.Stock CodeCATXPositionIndependent DirectorColleagues
- JMJohan M. SpoorCEO & Director
- LALori A. Holmes-WoodsChairperson of the Board
- JDJoel David SendekCFO & Principal Financial Officer
- MPMarkus PuhlmannChief Medical Officer
- MKMichael K. SchultzCo-Founder & Senior Scientific Advisor
- SCShane CobbExecutive Vice President of Operations
- RFRobert Froman WilliamsonIndependent Director
- HHHeidi HensonIndependent Director
